A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19
Francesca Capon, PhD
King’s College London
London, UK
IPC Councilor
Publication
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. Matthew T. Patrick, MEng PhD, Haihan Zhang, MS, Rachael Wasikowski, MS, Errol P. Prens, MD, PhD, Stephan Weidinger, MD, PhD, Johann E. Gudjonsson, MD, PhD, James T. Elder, MD, PhD, Kevin He, PhD, and Lam C. Tsoi, PhD. J Allergy Clin Immunol. 2021 Jan 21 doi: 10.1016/j.jaci.2021.01.006 [Epub ahead of print]
Commentary
Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19.
An article recently published in the Journal of Allergy and Clinical Immunology1 suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%. The authors of the study (Lam Tsoi and collaborators, University of Michigan) examined the medical records of 435,000 individuals, 1115 of whom had been diagnosed with COVID-19. After adjusting their analysis for the age, ethnicity, body mass index, and socioeconomic status of participants, they found that having an inflammatory skin disorder (acne, atopic dermatitis, or psoriasis) conferred an increased risk of COVID-19 while reducing the likelihood of requiring mechanical ventilation.
The authors next analyzed publicly available expression data and observed a significant overlap between the genes that are up-regulated in inflammatory skin diseases and those that are induced by SARS-CoV2 infection in bronchial epithelial cells. Of note, the shared genes were mostly involved in epidermal barrier function and innate antiviral responses.
In the final stage of the study, the authors re-examined published genome-wide association studies and found a marker that was associated with susceptibility to both psoriasis and COVID-19. Interestingly, the variant maps in proximity to S100A12, a gene that is up-regulated in psoriatic lesions and in SARS-CoV2 infected cells.
These observations suggest a link between skin inflammation and COVID-19 susceptibility. The authors speculate that in individuals with psoriasis or atopic dermatitis, SARS-CoV2 could enter the organism through the skin, exploiting defects in epidermal barrier function. Progression to severe disease would then be hindered by the activation of immune responses at sites of inflammation. While these hypotheses could be tested in animal models, the authors acknowledge that the underlying observations will need to be replicated in further genetic and epidemiological studies.
Reference:
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. MT Patrick et al. J Allergy Clin Immunol. Epub ahead of print: 20th Jan 2021. DOI: https://doi.org/10.1016/j.jaci.2021.01.006
Categories
Recent Posts
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)
Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Juul van den Reek, MD, PhD
Also Read
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.
Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast
A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study
The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.
Subscribe to the IPC Newsletter